Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. (“Heron”) or the (“Company”) (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Heron stock or options between October 31, 2018 and April 30, 2019 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
The lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all those who purchased Heron securities between October 31, 2018 and April 30, 2019 (the “Class Period”). The case, Wong v. Heron Therapeutics, Inc. et al., No. 3:19-cv-01038 was filed on June 3, 2019, and has been assigned to Judge Larry Alan Burns.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; and (2) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011.
On May 1, 2019, Heron announced receipt of a Complete Response Letter (“CRL”) from the FDA on April 30, 2019, regarding Heron’s NDA for HTX-011 for the management of postoperative pain (the “May 2019 Press Release”). In the May 2019 Press Release, Heron advised investors that “[t]he CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional CMC and non-clinical information.”
On this news, the Company's stock price fell from $21.68 per share on April 30, 2019 to $17.75 per share on May 1, 2019: a $3.93 or 18.13% drop.
Heron Therapeutics, Inc. (HTRX)
* The submission of this form does not create an attorney-client relationship.
Filed on 06/04/2019
Lead Plaintiff Deadline 08/05/2019
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Richard W. Gonnello email@example.com Phone (212) 983-9330 Fax (212) 983-9331